CD36 and breast cancer: This strategy, however, may not be effective in all tamoxifen-resistance breast cancer types, since in the same study, Liang et al., found MDA-MB-231, an ER-negative tamoxifen-resistant breast cancer cell line, had lower CD36 protein expression than non-resistant MCF7 [39].